Stock listing
Stuttgart:1KA GH Research PLC Aktie
German listing (Stuttgart) of GH Research PLC · home listing NASDAQ:GHRS
Follow GH Research PLC into a list and get an email when it puts out news.
Home listing price · NASDAQ:GHRS
$17.53 USD -0.72 (-3.9%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:GHRS
- Day range
- $17.29 – $18.32 USDNov 20, 2026
- Volume
- 298,833 sharesNov 20, 2026
- Market cap
- $1.20B USDAt the close on Nov 20, 2026 · price × 68.64M shares outstanding
- 52-week range
- $12.04 – $31.44 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $6.39M USDMedian day 255,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GHRS · Home | $17.53 USD | -0.72 (-3.9%) | 298,833 | $18.32 | $18.32 | $17.29 | $18.25 | Close on Nov 20, 2026 |
| Frankfurt:1KA | €15.90 EUR | -0.30 (-1.9%) | — | €16.40 | €16.40 | €15.90 | €16.20 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GHRS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $17.53 | -0.72 | -3.9% | $18.32 | $18.32 | $17.29 | 298,833 | |
| $18.25 | -0.02 | -0.1% | $18.29 | $18.74 | $18.02 | 461,981 | |
| $18.27 | -0.48 | -2.6% | $18.48 | $18.48 | $17.57 | 324,220 | |
| $18.75 | -0.35 | -1.8% | $19.10 | $19.49 | $18.27 | 634,013 | |
| $19.10 | +0.61 | +3.3% | $18.82 | $19.79 | $18.00 | 560,158 | |
| $18.49 | -0.76 | -3.9% | $19.01 | $19.09 | $17.96 | 191,830 | |
| $19.25 | -0.31 | -1.6% | $19.69 | $19.75 | $19.09 | 127,770 | |
| $19.56 | +0.30 | +1.6% | $19.04 | $19.85 | $18.83 | 108,739 | |
| $19.26 | +0.65 | +3.5% | $18.82 | $19.49 | $18.34 | 195,435 | |
| $18.61 | +0.17 | +0.9% | $18.56 | $18.78 | $18.15 | 453,631 | |
| $18.44 | -1.49 | -7.5% | $19.69 | $19.88 | $18.32 | 407,210 | |
| $19.93 | -0.35 | -1.7% | $20.73 | $20.87 | $18.29 | 297,754 | |
| $20.28 | -0.22 | -1.1% | $20.64 | $21.38 | $20.05 | 476,135 | |
| $20.50 | -0.36 | -1.7% | $20.91 | $21.28 | $19.96 | 542,837 | |
| $20.86 | -0.64 | -3.0% | $21.26 | $21.35 | $20.39 | 305,398 | |
| $21.50 | +0.79 | +3.8% | $20.77 | $22.12 | $20.77 | 345,100 | |
| $20.71 | +0.69 | +3.4% | $19.91 | $20.79 | $19.52 | 198,718 | |
| $20.02 | +0.84 | +4.4% | $19.18 | $20.22 | $18.75 | 299,970 | |
| $19.18 | +1.11 | +6.1% | $18.10 | $19.31 | $18.07 | 306,075 | |
| $18.07 | -0.43 | -2.3% | $18.46 | $18.59 | $17.54 | 699,207 | |
| $18.50 | -0.41 | -2.2% | $18.83 | $19.00 | $18.43 | 329,178 | |
| $18.91 | -0.255 | -1.3% | $19.22 | $19.81 | $18.81 | 393,899 | |
| $19.17 | +0.885 | +4.8% | $18.30 | $19.43 | $18.11 | 277,232 | |
| $18.28 | +0.13 | +0.7% | $18.22 | $19.07 | $18.02 | 323,287 | |
| $18.15 | -0.66 | -3.5% | $18.92 | $19.32 | $18.05 | 162,600 | |
| $18.81 | +0.25 | +1.3% | $18.75 | $19.39 | $18.48 | 276,700 | |
| $18.56 | -0.29 | -1.5% | $18.64 | $19.19 | $18.29 | 304,400 | |
| $18.85 | -1.17 | -5.8% | $19.88 | $19.90 | $18.72 | 425,500 | |
| $20.02 | -1.09 | -5.2% | $21.05 | $21.23 | $20.01 | 229,700 | |
| $21.11 | +0.66 | +3.2% | $20.66 | $21.30 | $20.45 | 146,000 | |
| $20.45 | -0.61 | -2.9% | $20.94 | $21.07 | $19.87 | 332,200 | |
| $21.06 | -0.46 | -2.1% | $21.39 | $22.17 | $21.00 | 304,600 | |
| $21.52 | -0.65 | -2.9% | $22.23 | $22.27 | $21.21 | 495,400 | |
| $22.17 | -0.77 | -3.4% | $23.00 | $23.00 | $21.86 | 207,000 | |
| $22.94 | +0.08 | +0.3% | $23.05 | $23.12 | $22.36 | 230,000 | |
| $22.86 | -0.62 | -2.6% | $23.31 | $23.90 | $22.53 | 255,100 | |
| $23.48 | -1.19 | -4.8% | $24.92 | $24.92 | $23.13 | 384,700 | |
| $24.67 | +1.25 | +5.3% | $23.39 | $24.99 | $23.12 | 1,131,900 | |
| $23.42 | -0.42 | -1.8% | $23.48 | $23.68 | $22.89 | 609,700 | |
| $23.84 | -0.61 | -2.5% | $24.48 | $24.55 | $23.49 | 180,000 | |
| $24.45 | -1.51 | -5.8% | $26.10 | $26.10 | $23.43 | 418,200 | |
| $25.96 | -1.90 | -6.8% | $28.13 | $28.13 | $25.67 | 178,800 | |
| $27.86 | -0.07 | -0.3% | $28.02 | $28.45 | $27.61 | 101,600 | |
| $27.93 | -0.33 | -1.2% | $28.48 | $28.50 | $27.76 | 131,100 | |
| $28.26 | -0.46 | -1.6% | $28.87 | $29.15 | $28.00 | 132,800 | |
| $28.72 | +0.97 | +3.5% | $28.11 | $29.17 | $27.76 | 501,200 | |
| $27.75 | +0.20 | +0.7% | $27.63 | $28.07 | $27.22 | 152,900 | |
| $27.55 | -0.34 | -1.2% | $27.63 | $27.83 | $26.52 | 140,300 | |
| $27.89 | +0.69 | +2.5% | $27.20 | $28.62 | $27.03 | 157,300 | |
| $27.20 | -0.08 | -0.3% | $27.57 | $28.11 | $27.01 | 159,200 | |
| $27.28 | -0.28 | -1.0% | $27.24 | $27.61 | $26.88 | 128,800 | |
| $27.56 | -0.23 | -0.8% | $27.77 | $27.92 | $26.46 | 336,800 | |
| $27.79 | -0.44 | -1.6% | $27.98 | $28.33 | $27.21 | 221,000 | |
| $28.23 | +0.31 | +1.1% | $27.86 | $28.31 | $27.26 | 78,100 | |
| $27.92 | -0.15 | -0.5% | $28.19 | $28.33 | $27.58 | 117,000 | |
| $28.07 | +0.71 | +2.6% | $27.46 | $28.32 | $27.09 | 111,900 | |
| $27.36 | +0.38 | +1.4% | $26.94 | $28.00 | $26.61 | 464,900 | |
| $26.98 | -0.96 | -3.4% | $27.86 | $28.07 | $26.68 | 149,200 | |
| $27.94 | -0.71 | -2.5% | $28.61 | $28.61 | $27.82 | 117,700 | |
| $28.65 | -0.36 | -1.2% | $29.02 | $29.08 | $28.44 | 73,500 | |
| $29.01 | +0.09 | +0.3% | $28.92 | $29.14 | $28.38 | 145,100 | |
| $28.92 | +0.82 | +2.9% | $28.46 | $29.13 | $28.46 | 113,100 | |
| $28.10 | -0.23 | -0.8% | $28.20 | $28.60 | $27.24 | 162,800 | |
| $28.33 | -0.35 | -1.2% | $28.83 | $29.22 | $28.01 | 141,700 | |
| $28.68 | -1.12 | -3.8% | $29.74 | $29.90 | $28.55 | 172,300 |
- Ticker
- Stuttgart:1KA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Nov 13, 2026
GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · Nov 13, 2026
Corporate Update (November 2026)
Corporate update · 19 slides
Latest news
GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 13, 2026
Closed $19.10 (+3.3%) on Nov 13, 2026
GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
Nov 13, 2026
Closed $19.10 (+3.3%) on Nov 13, 2026
GH Research Announces Publication of Phase 2a Postpartum Depression Results
Jun 4, 2026
Closed $23.25 (-4.8%) on Jun 4, 2026
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
Closed $22.21 (+1.5%) on May 14, 2026
GH Research Announces Pricing of $117.5 Million Underwritten Offering
Apr 29, 2026
Closed $19.16 (-3.5%) on Apr 29, 2026
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
Apr 20, 2026
Closed $21.50 (+17.2%) on Apr 20, 2026
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
Mar 25, 2026
Closed $13.65 (+1.9%) on Mar 25, 2026
GH Research Reports Full Year 2025 Financial Results and Provides Business Update
Mar 5, 2026
Closed $15.17 (-5.1%) on Mar 5, 2026
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
Jan 5, 2026
Closed $15.46 (+16.8%) on Jan 5, 2026
GH Research to Announce IND Status for GH001
Jan 2, 2026
Closed $13.24 (+4.3%) on Jan 2, 2026
GH Research PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 10 in the last 12 months · 42 in all · newest Nov 13, 2026 · oldest 2021
- Decks
- 37 decks · latest Nov 13, 2026
Where GH Research PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GHRS · Home listing | NASDAQ | United States | USD |
| gettex:1KA | gettex | Germany | EUR |
| Frankfurt:1KA | Frankfurt | Germany | EUR |
| Lang & Schwarz:A3CUAZ | Lang & Schwarz | Germany | EUR |
| LS Exchange:A3CUAZ | LS Exchange | Germany | EUR |
| Tradegate:1KA | Tradegate | Germany | EUR |
| BOATS:GHRS | BOATS | United States | USD |
| Dusseldorf:1KA | Dusseldorf | Germany | EUR |
| Munich:1KA | Munich | Germany | EUR |
| Stuttgart:1KA · This page | Stuttgart | Germany | EUR |
Valuation
Price/book 3.4× against a median of 3.2×: 5th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $841.0M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.28
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| GH Research PLC · NASDAQ:GHRS | US$1.20B | US$841.0M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 1.28 |
| MannKind Corporation · NASDAQ:MNKD | US$1.24B | US$1.46B | n/a | 3.5× | 309× | n/a | −18.1% | n/a | 1.06 |
| Novavax, Inc. · NASDAQ:NVAX | US$1.23B | US$902.3M | n/a | 2.2× | n/a | n/a | −18.6% | n/a | 1.98 |
| Silence Therapeutics PLC · NASDAQ:SLN | US$1.23B | US$984.6M | n/a | 2,159× | n/a | 5.7× | n/a | 0.0× | 1.07 |
| Ocular Therapeutix, Inc. · NASDAQ:OCUL | US$1.23B | US$774.9M | n/a | 15.4× | n/a | 2.8× | −648.6% | 0.2× | 1.35 |
| Generate Biomedicines, Inc. · NASDAQ:GENB | US$1.22B | US$895.6M | n/a | 28.1× | n/a | 3.2× | −637.0% | 0.2× | 1.90 |
| Taysha Gene Therapies, Inc. · NASDAQ:TSHA | US$1.21B | US$837.4M | n/a | 153× | n/a | 3.4× | n/a | 0.1× | 1.69 |
| Mineralys Therapeutics, Inc. · NASDAQ:MLYS | US$1.21B | US$585.1M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.39 |
| Vor Biopharma Inc. · NASDAQ:VOR | US$1.18B | US$697.4M | 0.9× | n/a | n/a | n/a | n/a | n/a | 1.25 |
| Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A · SZSE:300204 | US$1.17B | US$1.01B | n/a | 36.1× | n/a | 3.9× | −53.3% | 0.0× | n/a |
| OPKO Health, Inc. · NASDAQ:OPK | US$1.17B | US$1.26B | n/a | 2.5× | n/a | 1.0× | −29.5% | 0.4× | 0.90 |
| Median of the others | US$1.22B | US$899.0M | 0.9× | 21.7× | 309× | 3.2× | −41.4% | 0.1× | 1.35 |
Forecasts
7 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 42.89 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.14 · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Velichka Valcheva | Chief Executive Officer |
| Aaron Cameron | Chief Operating Officer |
| Julie Ryan | Vice President, Finance |
| Florian Schönharting | Chairman of the Board & Co-Founder |
| Magnus Halle | Managing Director, Ireland & Co-Founder |
| Vanina Popova | Chief Development Officer |
Board
| Director | Role |
|---|---|
| Florian Schönharting | Chairman of the Board & Co-Founder |
| Dermot Hanley | Director |
| Duncan Moore | Director |
| Michael Forer | Vice Chairman of the Board |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 13, 2026 · Before open | +3.3% |
| Q2 2026 | Aug 6, 2026 · Before open | +5.2% |
| Q1 2026 | May 14, 2026 · Before open | +1.5% |
| Q4 2025 | Feb 26, 2026 | −5.7% |
| Q3 2025 | Nov 6, 2025 · Before open | −1.3% |
| Q2 2025 | Aug 7, 2025 · Before open | −0.4% |
| Q1 2025 | May 8, 2025 · Before open | +5.2% |
| Q4 2024 | Feb 27, 2025 | −7.7% |
| Q3 2024 | Nov 14, 2024 · Before open | −2.9% |
| Q2 2024 | Sep 3, 2024 | −19.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 3, 2024 · Before open | +4.4% |
| Q4 2023 | Feb 29, 2024 · Before open | +7.9% |
| Q3 2023 | Nov 9, 2023 · After close | +3.3% |
| Q2 2023 | Aug 23, 2023 · Before open | −1.9% |
| Q1 2023 | May 11, 2023 · Before open | +3.6% |
| Q4 2022 | Mar 2, 2023 · Before open | −2.7% |
| Q3 2022 | Nov 10, 2022 · Before open | +7.0% |
| Q2 2022 | Aug 23, 2022 · Before open | +5.3% |
| Q1 2022 | May 18, 2022 · Before open | −10.0% |
| Q4 2021 | Mar 28, 2022 · Before open | +1.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (November 2026) | Corporate update | 19 slides | Nov 13, 2026 |
| Investor Presentation (August 2026) | Investor deck | 19 slides | Aug 6, 2026 |
| Investor Presentation (May 2026) | Investor deck | 17 slides | May 14, 2026 |
| Investor Presentation (March 2026) | Investor deck | 17 slides | Mar 5, 2026 |
| ACNP 2026 | Conference | 46 slides | Jan 15, 2026 |
| Technical Presentation (January 2026) | Technical | 20 slides | Jan 13, 2026 |
| Investor Presentation (January 2026) | Investor deck | 17 slides | Jan 5, 2026 |
| ACNP 2026 Mini Panel | Conference | 43 slides | January 2026 |
| ESG Presentation (December 2025) | Sustainability | 6 slides | Dec 3, 2025 |
| Investor Presentation (November 2025) | Investor deck | 14 slides | Nov 6, 2025 |
All 37 decks
Financings
| Raise | Date |
|---|---|
| Public offering of ordinary shares Announced: about US$117.5M · US$18 a share · Stifel +4 Dealers: Stifel (lead), Cantor (lead), RBC Capital Markets (lead), Canaccord Genuity (co-lead), Citizens Capital Markets (co-lead) Buyers: Lynx1 Capital Management (initiated the offering); Deep Track Capital; Foresite Capital | Apr 29, 2026 |
| Public offering of ordinary shares Update: about US$150M · US$15 a share · Cantor +4 Dealers: Cantor (lead), Stifel (lead), RBC Capital Markets (lead), Canaccord Genuity (co-lead), Citizens JMP (co-lead) | Feb 5, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Jun 24, 2021.
- Price
- US$16.00 a share
- Shares offered
- 10,000,000 ordinary shares
- Offering size
- US$160 million
- Underwriters' option
- Up to 1,499,999 more shares
- Listing
- GHRS on the Nasdaq Global Market
- Underwriters
- Cowen, Stifel, Canaccord Genuity, JMP Securities · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 20, 2021 |
| Filed publicly | Jun 4, 2021 |
| Amended once | Jun 21, 2021 |
| Shares registered with an exchange | Jun 22, 2021 |
| Declared effective by the SEC | Jun 24, 2021 |
| Final prospectus, with the price | Jun 28, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 28, 2021 |
| EFFECT · Notice that a registration is effective | Jun 24, 2021 |
| F-1MEF · Registration of more shares for the same offering | Jun 24, 2021 |
| CERT · Exchange's certificate of listing | Jun 23, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 22, 2021 |
| CORRESP · Letter to the SEC | Jun 22, 2021 |
| CORRESP · Letter to the SEC | Jun 22, 2021 |
| CORRESP · Letter to the SEC | Jun 21, 2021 |
| F-1/A · Registration statement, amended | Jun 21, 2021 |
| UPLOAD · Letter from the SEC | Jun 18, 2021 |
All 14 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 4, 2021 |
| F-1 · Registration statement | Jun 4, 2021 |
| UPLOAD · Letter from the SEC | May 18, 2021 |
| DRS · Draft registration statement | Apr 20, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 28, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 335.0K | 315.0K | 315.0K | 47.0K | 19.0K | ||
| Gross profit | -335.0K | -315.0K | -315.0K | -47.0K | -19.0K | ||
| Research and development | 38.8M | 35.0M | 29.8M | 20.5M | 8.55M | 338.0K | 296.0K |
| Selling, general and administrative | 22.0M | 15.3M | 11.4M | 10.1M | 6.55M | 108.0K | 14.0K |
| Operating income | -60.7M | -50.3M | -41.2M | -30.6M | -15.1M | -446.0K | -310.0K |
| Depreciation and amortization | 335.0K | 315.0K | 315.0K | 47.0K | 19.0K | 0 | 0 |
| EBITDA | -60.4M | -50.0M | -40.9M | -30.5M | -15.1M | -446.0K | -310.0K |
| Interest expense | 463.0K | 717.0K | 63.0K | 0 | 9.00K | 0 | 0 |
| Income before tax | -48.3M | -39.0M | -35.6M | -22.5M | -9.20M | -446.0K | -310.0K |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -48.3M | -39.0M | -35.6M | -22.5M | -9.20M | -446.0K | -310.0K |
| Earnings per share, basic | -0.79 | -0.75 | -0.68 | -0.43 | -0.21 | -0.02 | -0.01 |
| Earnings per share, diluted | -0.79 | -0.75 | -0.68 | -0.43 | -0.21 | -0.02 | -0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 246.3M | 100.8M | 78.4M | 166.0M | 276.8M | 5.89M | 498.0K |
| Short-term investments | 34.5M | 48.5M | 83.1M | 0 | |||
| Receivables | 1.29M | 1.73M | 178.0K | 90.0K | 48.0K | 6.00K | |
| Inventory | -178.0K | -90.0K | 3.01M | -6.00K | |||
| Current assets | 286.0M | 154.2M | 164.1M | 168.5M | 279.8M | 5.91M | 504.0K |
| Property, plant and equipment | 620.0K | 748.0K | 1.07M | 97.0K | 82.0K | 0 | |
| Total assets | 288.2M | 188.3M | 226.3M | 254.4M | 279.9M | 5.91M | 504.0K |
| Accounts payable | 3.77M | 3.74M | 3.49M | 1.87M | 883.0K | 1.00K | 93.0K |
| Current liabilities | 8.38M | 8.95M | 6.70M | 4.55M | 2.75M | 246.0K | 104.0K |
| Total debt | 0 | 0 | 0 | 0 | 0 | ||
| Total liabilities | 8.53M | 9.32M | 7.33M | 4.55M | 2.75M | 246.0K | 104.0K |
| Shareholders' equity | 279.7M | 179.0M | 219.0M | 249.8M | 277.2M | 5.67M | 400.0K |
| Shares outstanding | 61.0M | 52.0M | 52.0M | 52.0M | 52.0M | 30.4M | 28.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -43.6M | -42.3M | -33.3M | -26.2M | -15.3M | -330.0K | -289.0K |
| Capital spending | -121.0K | -49.0K | -100.0K | -67.0K | -104.0K | 0 | 0 |
| Free cash flow | -43.7M | -42.3M | -33.4M | -26.3M | -15.4M | -330.0K | -289.0K |
| Cash from investing | 46.2M | 65.1M | -54.1M | -84.7M | -104.0K | 0 | -104.0K |
| Cash from financing | 139.7M | -304.0K | -204.0K | 0 | 286.4M | 5.50M | 797.0K |
| Change in cash | 142.3M | 22.5M | -87.6M | -110.9M | 271.1M | 5.17M | 508.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 13, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Oct 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 11, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
Show 200 filings
This page holds 200 of 203 filings. Open Filings
Cap table
Built by 6ix from GH Research PLC’s releases · as of Apr 29, 2026
- Common shares
- 68,642,287
- Fully diluted
- 68,642,287
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 68,642,287 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 68,642,287 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Duncan Moore Other companies: ASP Isotopes Inc. (Partner at East West Capital Partners · Since at least Nov 9, 2022); Allarity Therapeutics, Inc. (Director · Dec 20, 2021 – Dec 20, 2021 · Past) | Director · Since at least Mar 18, 2026 |
| Aaron Cameron | Chief Operating Officer · Since at least Mar 18, 2026 |
| Dermot Hanley | Director · Since at least Mar 18, 2026 |
| Florian Schönharting | Chairman of the Board & Co-Founder · Since at least Apr 1, 2026 |
| Julie Ryan | Vice President, Finance · Since at least Mar 18, 2026 |
| Magnus Halle | Managing Director, Ireland & Co-Founder · Since at least Mar 18, 2026 |
| Michael Forer | Vice Chairman of the Board · Since at least Mar 18, 2026 |
| Vanina Popova | Chief Development Officer · Since at least Nov 13, 2026 |
| Velichka Valcheva | Chief Executive Officer · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about GH Research PLC.